African Pharmaceutical Directory 2012

The market potential of the African pharmaceutical and biotechnology sector is enormous and business opportunities abound. However, unraveling the maze of who’s who, and who does what is a daunting task. Here’s the solution you’ve been looking for.

This new edition of The African Pharmaceutical Directory has been thoroughly researched, to bring you a completely up-to-date guide to the African ever-changing pharmaceutical industry.

If you need to source from, or sell to Pharmaceuticals, Biotechnology products, Biopharmaceuticals, Bulk Pharmaceuticals, OTC/Healthcare products, Research & Development, Fine Chemicals, Generics, Genomics, or Diagnostics/Reagents; or, if you’re looking to break into this appealing market, the new African Pharmaceutical Directory will provide you with thousands of fresh business contacts – and help you keep track of old ones – quickly and easily.

This one directory covers the entire the African pharmaceutical & biotechnology industries sector.

This Directory will enable you to:

* Profile a market
* Build new business prospects
* Pinpoint key executives
* Generate new customers
* Discover who your competitors are
* Make vital contacts
* Save the time, money and effort of doing your own research
* Identify alternative suppliers and manufacturers
* Source up-to-date company information
* Access a wealth of quality information on companies and key personnel

Whether you are a product manager, in charge of marketing or simply interested to remain in touch with the latest developments in the African pharmaceutical industry, this Directory will save you time and effort in finding the up-to-date information you need.

For just US$150.00 The African Pharmaceutical Directory gives you instant access to a wealth of accurate information.

Look at the depth of information you’ll get in The African Pharmaceutical Directory

* Company contact details.
* Telephone, Fax, Email and Web addresses.
* Names of key management and trading personnel.
* Product information.

6 Great reasons to order your copy of The African Pharmaceutical Directory:

1. Save time: no need to search the Internet, all the information you need is in one handy guide;
2. Save money: by using a resourceful book that details all your business contacts activities;
3. Gain an understanding of the key players in this increasingly dominant market: quickly and easily;
4. Source the right trader/producer: by identifying products quickly;
5. Discover new business leads: and grow your business;
6. Update your contact list: from the most reliable source in the industry.

Why wait? If you’re are buying or selling pharmaceuticals in Africa, or wishing to do so, this directory is essential for you. Where else will you find such a broad depth of both key contact and production information for the African pharmaceutical industry in one handy reference source?

To know more about this report:
http://www.researchkart.com/product/10411/African-Pharmaceutical-Directory-2012.html
or email us at shreya@researchkart.com

 

VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011

Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for many cancers, including colorectal and non-small cell lung cancer.

While VEGF inhibitors such as bevacizumab (Avastin®) provide valuable treatment options, these benefits are not seen in all patients and cancer types. Today, there is an urgent need for predictive biomarkers to enable those patients most likely to benefit from VEGF inhibition, to be identified. This report (see brochure) provides a review of findings to date on biomarkers associated with the use bevacizumab (Avastin®); both therapy-indicating and prognostic.

The identification of therapy-indicating and prognostic biomarkers relating to antiangiogenic therapy is in its early stages, however important advances have been made. This report identifies the latest findings on ten different cancers and includes an evaluation of candidate biomarkers as a basis for interpreting patient outcomes according to RECIST criteria, and evaluates existing bevacizumab-containing treatments and drug combinations.

Key content:

• A comprehensive review of clinical studies that have identified biomarkers that are either therapy-indicating in respect of bevacizumab (Avastin®) or indicative of patient prognosis
• Biomarkers identified or further evaluated in the last three years, up until October 2011. From a background of extensive research on bevacizumab (Avastin®) and VEGF-related biomarkers, the most important findings have been identified for their significance and value to patients and in designing clinical trials
• Covering more than ten cancers including colorectal, ovarian, renal, breast, pancreatic, prostate, lung and liver cancers
• Findings based on clinical trial findings including patient numbers, statistics and RECIST criteria
• Studies indicate drug type associations together with comparative therapies
• Descriptions and explanation of all biomarkers identified (proteins, genotypes, imaging etc)
• Biomarker associations are categorised according to three broad criteria, namely “positive-therapy-indicating” (response, improved response, improved outcome or prognosis), “non-therapy-indicating” (no differences in tumour response, outcome or prognosis) and “negative-therapy-indicating” (adverse events, poor outcome or prognosis)

Table of Content

To know more about this report:
VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011 or email us at shreya@researchkart.com